Want to see ELTP full AI Analyst Report?
ELTP Stock Chart & Stats
$0.38
-$0.01(-2.79%)
At close: 4:00 PM EDT
$0.38
-$0.01(-2.79%)
Day’s Range― - ―
52-Week Range$0.27 - $0.74
Previous CloseN/A
Volume72.14K
Average Volume (3M)951.20K
Market Cap
$331.76M
Enterprise Value$378.71
Total Cash (Recent Filing)$38.94M
Total Debt (Recent Filing)$2.65M
Price to Earnings (P/E)5.7
Beta1.21
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding1,077,136,500
10 Day Avg. Volume753,540
30 Day Avg. Volume951,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.93
Price to Sales (P/S)2.61
P/FCF Ratio0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scale And Revenue ExpansionThe sharp annual expansion shows Elite is converting recent product launches into meaningful scale. A broader own-label portfolio can improve manufacturing leverage, customer reach and the foundation for sustained growth beyond a single product.
Pipeline And Product DiversificationNew launches and development candidates extend Elite beyond its existing franchises into neurology and other large generic markets. Multiple pipeline opportunities diversify future revenue sources, although approvals and commercialization remain necessary.
Strong Balance Sheet And ProfitabilityHigh recent margins combined with minimal leverage give Elite financial flexibility to fund R&D, facility improvements and launches without heavy interest burden. This conservative balance sheet supports resilience as the product portfolio develops.
Bears Say
Competitive Margin PressureThe setback demonstrates the vulnerability of generic pharmaceuticals to price competition, particularly when a major franchise drives results. Continued pricing pressure could reduce the profitability and cash contribution of recently launched products.
Customer Concentration RiskDependence on one customer increases bargaining power for wholesalers and raises the impact of contract, inventory or purchasing changes. Concentration may constrain pricing and make revenue less predictable while Elite scales its customer base.
Cash Conversion And Funding UncertaintyOperating cash flow has not fully matched reported earnings and free cash flow growth is declining, reducing confidence in earnings quality. Potential warrant dilution could further affect per-share economics and complicate future capital planning.
Elite Pharmaceuticals News
ELTP FAQ
What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.27 and its highest was $0.74 in the past 12 months.
What is Elite Pharmaceuticals’s market cap?
Elite Pharmaceuticals’s market cap is $331.76M.
When is Elite Pharmaceuticals’s upcoming earnings report date?
Elite Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 90 days.
How were Elite Pharmaceuticals’s earnings last quarter?
Elite Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported $0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Elite Pharmaceuticals overvalued?
According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued.
Does Elite Pharmaceuticals pay dividends?
Elite Pharmaceuticals does not currently pay dividends.
What is Elite Pharmaceuticals’s EPS estimate?
Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elite Pharmaceuticals have?
Elite Pharmaceuticals has 1,077,136,500 shares outstanding.
What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
Elite Pharmaceuticals reported an EPS of $0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.556%.
Which hedge fund is a major shareholder of Elite Pharmaceuticals?
Currently, no hedge funds are holding shares in ELTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elite Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELTP Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 82.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.04%
Trailing 12-Months
Company Description
Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
ELTP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and strategic outlook: quarterly revenues and operating profit were steady, volumes and market share increased, pipeline progress included launches, filings and BE success, cash and R&D investment improved, and management has active plans for NASDAQ uplisting and M&A. Offsetting these positives are YoY comparisons to an unusually strong prior-quarter that create headline declines, a drop in quarter-over-quarter operating cash versus that exceptional period, higher customer concentration (60% of revenues), COGS pressures from product mix (notably Naltrexone), an unresolved FDA issue for Oxy ER that risks timing, and near-term warrant-related uncertainty. On balance the company’s financial position, pipeline momentum, and strategic opportunities outweigh the noted execution and timing risks.View all ELTP earnings summariesTechnical Analysis
ANI Pharmaceuticals
―
Cumberland Pharmaceuticals
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―
Eton Pharmaceuticals
―
Ownership Overview
0.96% Insiders
<0.01% Other Institutional Investors
99.04% Public Companies and
Individual Investors










